Filing Flows › Industrials › Bionano Genomics (BNGO)
Bionano Genomics (BNGO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 10, 2026 · Bionano Genomics (BNGO) Q2 2026 earnings results →
Q2 2026 Revenue up 21% year over year to $8.2M · 91¢ of every $1 of revenue lost · operating margin -88.3%
Bionano Genomics made $8.2M in Q2 2026 (+21% Y/Y): Product $7.7M, Product and Service Other $478K. Operating margin -88.3%, net loss $7.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 10, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $8.2M in Q2 2026, up 21% year over year and up 22% from the previous quarter. Consumable Revenue was the largest line at 52% of revenue. Consumable Revenue added $1.0M year over year (up 31%), 70% of the total change. Software Revenue declined 16%.
Operating costs exceeded revenue by $7.2M, an operating margin of -88.3%. Total costs grew 6% against revenue growth of 21%. The fastest-growing cost line was Cost of revenue (+18%). The quarter ended with a net loss of $7.4M, narrower than the previous quarter's $8.3M loss.
Operating cash flow was −$4.7M. Non-cash charges added back $2.3M of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items used $513K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 10, 2026 | $8.2M | +21% | -88.3% | −$7.4M | −$4.7M |
| Q1 2026 | 10-Q | May 13, 2026 | $6.7M | +4% | -118.1% | −$8.3M | −$5.7M |
| Q4 2025 | 10-K | Mar 23, 2026 | $8.0M | -3% | -107.4% | −$7.9M | −$4.2M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $7.4M | +21% | -115.9% | −$8.5M | −$5.9M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $6.7M | -13% | -115.8% | −$6.9M | −$3.5M |
| Q1 2025 | 10-Q | May 14, 2025 | $6.5M | -26% | -131.1% | −$3.1M | −$2.8M |
| Q4 2024 | 10-K | Mar 31, 2025 | $8.2M | -24% | -146.3% | −$20.1M | −$6.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Bionano Genomics
We are a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (“OGM”) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research, and for other applications including bioprocessing. We offer a platform-agnostic software solution, which integrates next-generation sequencing, microarray and OGM data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company also offers nucleic acid extraction and purification solutions using proprietary isotachophoresis ITP technology.
In its own words, from its 10-K, filed Mar 31, 2025.
Bionano Genomics against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +21% against the peers' median +5%. Operating margin: -88.3% against the peers' median 8.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BNGO Bionano Genomics | Q2 2026 | $8.2M | +21% | -88.3% |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
Source: Bionano Genomics 10-Q on SEC EDGAR · CIK 1411690 · Laboratory Analytical Instruments
13F: who owns BNGO and who is buying
More on BNGO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results